Director Meghan Joyce sold 2,896 shares of Guardant Health Inc (GH, Financial) on November 13, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 7,648 shares of the company.
Guardant Health Inc is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The company's liquid biopsy tests are designed to provide comprehensive genomic results about the cancer from a simple blood draw.
Over the past year, Meghan Joyce has sold a total of 3,196 shares of Guardant Health Inc and has not made any purchases of the stock. The insider transaction history for Guardant Health Inc shows a pattern of more sales than purchases among insiders, with 1 insider buy and 6 insider sells over the past year.
Shares of Guardant Health Inc were trading at $29.9 on the day of the transaction. The company has a market cap of approximately $3.73 billion. According to the GF Value, the stock is currently modestly undervalued, with a price-to-GF-Value ratio of 0.78, suggesting potential upside from its current trading price.
The GF Value of $38.16 for Guardant Health Inc is derived from historical trading multiples including price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from analysts.
This recent sale by the insider could be of interest to current and potential investors, providing insight into insider sentiment and potential future stock performance based on the company's valuation and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
